See the DrugPatentWatch profile for Vyndaqel
When does the Vyndaqel patent expire?
I can’t give a specific expiry date for “Vyndaqel” from the information provided. “Vyndaqel” (tafamidis, for transthyretin amyloid cardiomyopathy) has multiple intellectual-property layers (different compound/process and method-of-use patents, plus extensions in each country), so the relevant date depends on the jurisdiction (e.g., US vs. EU vs. UK) and which particular claim type is being considered.
Which patents cover Vyndaqel, and what do they protect?
“Vyndaqel” intellectual property typically spans:
- The active ingredient (tafamidis) and related chemical/compound claims.
- Manufacturing processes (how the drug is made).
- Methods of treatment (for particular disease indications such as transthyretin amyloid cardiomyopathy).
- Country-specific exclusivities and, in some jurisdictions, supplementary protection mechanisms.
A precise answer needs the specific patent numbers or at least the country of interest.
What happens to generic or biosimilar competition if the patent expires?
If a relevant patent protecting tafamidis expires (or is found invalid/doesn’t cover a product), other manufacturers may be able to seek market approval for competing products, subject to:
- Regulatory approval requirements for quality, safety, and efficacy.
- Remaining barriers such as other still-active patents or regulatory exclusivity.
Because patents can vary by claim and geography, competition timing can differ even when one patent reaches its expiry.
Are there patent challenges or court cases that affect launch timing?
Patent challenges can delay or accelerate entry depending on outcomes (for example, an injunction can block marketing while a case is pending). To answer this, I’d need the jurisdiction and the specific competitor/product you mean.
Which country’s “Vyndaqel patente” are you asking about?
Tell me the country (France/EU/US/UK/etc.) or share any patent number you’re looking at, and I can help interpret what that particular patent covers and how it relates to market exclusivity timing.